AR065816A1 - Regimen anticonceptivo oral - Google Patents

Regimen anticonceptivo oral

Info

Publication number
AR065816A1
AR065816A1 ARP080101187A ARP080101187A AR065816A1 AR 065816 A1 AR065816 A1 AR 065816A1 AR P080101187 A ARP080101187 A AR P080101187A AR P080101187 A ARP080101187 A AR P080101187A AR 065816 A1 AR065816 A1 AR 065816A1
Authority
AR
Argentina
Prior art keywords
oral contraceptive
estradiol
beta
oral
days
Prior art date
Application number
ARP080101187A
Other languages
English (en)
Inventor
Jean-Louis Thomas
Original Assignee
Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramex filed Critical Theramex
Publication of AR065816A1 publication Critical patent/AR065816A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Un método monofásico para lograr la anticoncepcion en una mujer, que consiste en administrar oralmente a la mujer una composicion que comprende 1,5 mg de 17-beta--estradiol y 2,5 mg de acetato de nomegestrol durante 24 días, seguido de un períodolibre de hormonas de 4 días. Reivindicacion 11: Una composicion hormonal oral que comprende 1,5 mg de 17-beta-estradiol y 2,5 mg de acetato de nomegestrol para utilizar como un producto anticonceptivo oral para ser administrado durante 24 díasseguido de un período de 4 días libre de hormona. Reivindicacion 12: El uso de una composicion hormonal oral que comprende 1,5 mg de 17-beta-estradiol y 2,5 mg de acetato de nomegestrol para la preparacion de un producto anticonceptivo oral paraser administrado durante 24 días seguido de un período de 4 días libre de hormona. Reivindicacion 13: Un producto anticonceptivo oral que comprende 24 unidades de dosis, cada una de las cuales comprende 1,5 mg de 17-beta-estradiol y 2,5 mg deacetato de nomegestrol. Reivindicacion 14: El producto anticonceptivo oral de acuerdo con la reivindicacion 13, que además comprende 4 unidades de dosis de placebo.
ARP080101187A 2007-03-26 2008-03-25 Regimen anticonceptivo oral AR065816A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92032607P 2007-03-26 2007-03-26

Publications (1)

Publication Number Publication Date
AR065816A1 true AR065816A1 (es) 2009-07-01

Family

ID=39672648

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101187A AR065816A1 (es) 2007-03-26 2008-03-25 Regimen anticonceptivo oral

Country Status (10)

Country Link
US (1) US20080242650A1 (es)
AR (1) AR065816A1 (es)
AU (1) AU2008231744A1 (es)
BR (1) BRPI0809089A2 (es)
CA (1) CA2682049A1 (es)
CL (1) CL2008000866A1 (es)
MX (1) MX2009010320A (es)
PE (1) PE20081895A1 (es)
TW (1) TWI472332B (es)
WO (1) WO2008116873A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
AR066166A1 (es) * 2007-09-21 2009-07-29 Organon Nv Sistema de suministro de droga
US9192614B2 (en) 2008-10-08 2015-11-24 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
EP2343963B1 (en) 2008-10-08 2019-04-10 Agile Therapeutics, Inc. Transdermal delivery
ES2795455T3 (es) 2008-10-08 2020-11-23 Agile Therapeutics Inc Suministro transdérmico
WO2010111488A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
US10596103B2 (en) 2013-12-11 2020-03-24 Merek Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
JPS61243059A (ja) * 1985-04-19 1986-10-29 Konishi Kagaku Kogyo Kk 高純度4,4′−ジヒドロキシジフエニルスルホンの製造法
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5674863A (en) * 1991-10-18 1997-10-07 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
FR2737411B1 (fr) * 1995-08-01 1997-10-17 Theramex Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques
US5888543A (en) * 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
FR2754179B1 (fr) * 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
CA2507509A1 (en) * 2002-11-25 2004-06-10 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for respiratory disease containing 4-hydroxypiperidine derivative as active ingredient

Also Published As

Publication number Publication date
TWI472332B (zh) 2015-02-11
US20080242650A1 (en) 2008-10-02
PE20081895A1 (es) 2009-01-26
BRPI0809089A2 (pt) 2014-09-09
MX2009010320A (es) 2010-01-20
TW200902031A (en) 2009-01-16
WO2008116873A1 (en) 2008-10-02
AU2008231744A1 (en) 2008-10-02
CL2008000866A1 (es) 2008-10-03
CA2682049A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
AR065816A1 (es) Regimen anticonceptivo oral
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
CO6251259A2 (es) Formulaciones farmaceuticas de estriol en baja dosis
JP2010525050A5 (es)
MX2007013137A (es) Regimen anticonceptivo con dosificacion de estrogeno ampliada.
MX2008011074A (es) Metodo anticonceptivo oral multifasico de ciclo prolongado.
BRPI0514180A (pt) composto, composição farmacêutica, uso de um composto, kit farmaceuticamente útil adaptado para administração oral diária, e, métodos de preparação de um composto, e de contracepção em um mamìfero
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
JP2013529665A5 (es)
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
JP2009512658A5 (es)
AU2012293593A8 (en) Use of estetrol as emergency contraceptive
AR065580A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
JP2013516493A5 (es)
CA2468748A1 (en) Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
JP2011507853A5 (es)
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
AR065971A1 (es) Nuevo regimen de drosperinona/17beta-estradiol, producto farmaceutica combinado y conjunto de elementos (kit) para su aplicacion
NO20072687L (no) Farmasoytisk prevensjonspreparat
JP2005532336A5 (es)
MD3121G2 (ro) Metodă de profilaxie a hepatitei virale B
PH12019501607A1 (en) Tapentadol nasal composition
HRP20200155T1 (hr) Farmaceutski pripravak koji obuhvaća drospirenon i kontracepcijski komplet
MD335Y (en) Method for preparing the neck of uterus for induction of delivery in pregnants with prolonged pregnancy

Legal Events

Date Code Title Description
FB Suspension of granting procedure